Biotech Stock Rapt Crashes 72% To Record Low After Side Effect Sidelines Two Clinical Studies – Investor's Business Daily
Business News
- Biotech Stock Rapt Crashes 72% To Record Low After Side Effect Sidelines Two Clinical Studies Investor’s Business Daily
- FDA Puts Clinical Hold on RAPT Therapeutics’ Lead Candidate in Two Trials BioSpace
- RAPT faces ‘unfortunate and unexpected’ clinical hold after liver failure in atopic dermatitis trial FierceBiotech
- FDA puts on hold two drug trials of Rapt Therapeutics in ‘major setback’ The Indian Express
- RAPT Therapeutics stock plunges as FDA halts two clinical trials MarketWatch
Source: Business News